Although the mechanisms driving these differential MET still remains to be elucidated, overall, we show that the PD0325901 and Saracatinib combination can effectively be used in combination to strongly drive cancer cells towards a more epithelial state through up-regulation of E-cadherin across most of the NSCLC lines tested. The gene discussed is CDH1; the disease is cancer.